Interstitial Lung Fibrosis – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23689IDB-L5

Select Item

Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions.

Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking, and exposure to radiation are common factors while SOB, discomfort in the chest, loss of appetite, dry cough are common symptoms. Validated by chest x-ray, biopsy, bronchoscopy, PFT. Corticosteroids are prescribed to treat inflammation, oxygen therapy if breathlessness and other symptomatic management.

The Interstitial Lung Fibrosis drugs in development market research report provide comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Lung Fibrosis and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Interstitial Lung Fibrosis
Key Targets
· Lysophosphatidic Acid Receptor 1; Fibroblast Growth Factor Receptor 1; Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2; Rho Associated Protein Kinase 2; Proto Oncogene Tyrosine Protein Kinase Src; Receptor Type Tyrosine Protein Kinase FLT3; Tyrosine Protein Kinase Lck; Vascular Endothelial Growth Factor Receptor ; Transforming Growth Factor Beta 1 Proprotein; and Platelet Derived Growth Factor Receptor Beta
Key Mechanisms of Action
· Lysophosphatidic Acid Receptor 1 Antagonist; Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 Inhibitor; Rho Associated Protein Kinase 2 Inhibitor; Proto Oncogene Tyrosine Protein Kinase Src Inhibitor; Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor; Platelet Derived Growth Factor Receptor Beta Inhibitor; Platelet Derived Growth Factor Receptor Alpha Inhibitor; Transforming Growth Factor Beta 1 Proprotein Inhibitor; Tyrosine Protein Kinase Lck Inhibitor; and Vascular Endothelial Growth Factor Receptor 2 Inhibitor
Key Routes of Administration
· Oral; Inhalational; Intravenous; Parenteral; Subcutaneous; Topical; Nasal; Intravenous Drip; Intraperitoneal; and Subconjunctival
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Cell Therapy; Biologic; Oligonucleotide; Synthetic Peptide; Peptide; Antisense RNAi Oligonucleotide; Antisense Oligonucleotide; and Gene Therapy
Major Companies
· Createrna Science and Technology Co Ltd; AstraZeneca Plc; Boehringer Ingelheim International GmbH; MD Healthcare Inc; Nextgen Bioscience; inCerebro Co Ltd; HEC Pharma Co Ltd; F. Hoffmann-La Roche Ltd; BreStem Therapeutics Inc; and Bridge Biotherapeutics Inc

Scope

  • Therapeutics in Development: Covering 343 molecules, with 327 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Interstitial Lung Fibrosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Interstitial Lung Fibrosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Interstitial Lung Fibrosis treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

3+2 Pharma LLC
9 Meters Biopharma Inc
Accendatech Co Ltd
Accro Bioscience Suzhou Co Ltd
Acrobat Genomics Inc
AdAlta Ltd
Aeon Respire Inc
Afimmune Biopharma Ltd
Agency for Science
Technology and Research
AgomAb Therapeutics NV
Aileron Therapeutics Inc
Akeso Inc
AKSO Biopharmaceutical Inc
Alevin Therapeutics Ltd
Algernon Pharmaceuticals Inc
Altay Therapeutics Inc
Aluda Pharmaceuticals Inc
AlveoGene Ltd
Alveolus Bio Inc
Amakos Biotherapeutics Inc
Amgen Inc
AmMax Bio Inc
Amniotics AB
Amplia Therapeutics Ltd
AnaMar AB
Annji Pharmaceutical Co Ltd
Apaxen
APIE Therapeutics Inc
Aqua Therapeutics Co Ltd
Aqualung Therapeutics Corp
Aria Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Arroyo BioSciences LLC
AstraZeneca Plc
Atrapos Therapeutics LLC
Audax Therapeutics Ltd
AusBio Ltd
Austhera BioSciences Inc
Autotelic Bio Inc
Avalyn Pharma Inc
Aviceda Therapeutics Inc
Baylx Inc
Beijing Tide Pharmaceutical Co Ltd
BerGenBio ASA
Biolexis Therapeutics Inc
Bioven Group
Bioxytran Inc
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Bonac Corp
BreStem Therapeutics Inc
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
Calliditas Therapeutics AB
CarthroniX Inc
Ceapro Inc
Cedars-Sinai Medical Center
CellionBioMed Inc
CELLnLIFE Inc
Celon Pharma SA
Centre for Drug Design and Discovery
Centre National de la Recherche Scientifique
Certa Therapeutics Pty Ltd
Chemomab Therapeutics Ltd
Chengdu Huitai Biomedicine Co Ltd
Chengdu Zeling Biomedical Technology Co Ltd
Chiba University
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp.
Citryll BV
Collaborations Pharmaceuticals Inc
Createrna Science and Technology Co Ltd
CrystalGenomics Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
Curamys Co Ltd
Cynata Therapeutics Ltd
Cytonus Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
DICE Therapeutics Inc
DJS Antibodies Ltd
e-Therapeutics Plc
EffectorBio Inc
Elicio Therapeutics Inc
Elixiron Immunotherapeutics Inc
EmphyCorp Inc
Endeavor BioMedicines
Endogena Therapeutics Inc
Enzyvant Sciences Ltd
Epigen Biosciences Inc
Epirium Bio Inc
Epitracker Inc
ethris GmbH
Excalibur Pharmaceuticals Inc
Exorphia Co Ltd
Eyestem Research Pvt Ltd
F. Hoffmann-La Roche Ltd
Faknostics LLC
FibroBiologics Inc
FibroStatin SL
Foresee Pharmaceuticals Co Ltd
Galmed Pharmaceuticals Ltd
Gatehouse Bio
Genentech USA Inc
Genflow Biosciences Srl
Genome Protection Inc
Genosco Inc
Glycomantra Inc
GSNO Therapeutics Inc
Guangdong Raynovent Biotech Co Ltd
Guangzhou Henovcom Bioscience Co Ltd
Gubra ApS
H4Orphan Pharma
Hainan Haiyao Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
HEC Pharma Co Ltd
Heilongjiang ZBD Pharmaceutical Co Ltd
Hepion Pharmaceuticals Inc
Horizon Therapeutics Plc
Huabo Biopharm (Shanghai) Co Ltd
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
Humanetics Corp
HuniLife Biotechnology Inc
Imago Pharmaceuticals Inc
Immunomet Therapeutics Inc
inCerebro Co Ltd
Inhalis Therapeutics SA
Innovative Precision Medicine Group
Innovo Therapeutics Co Ltd
InSilico Medicine
Inventiva SA
Inversago Pharma Inc
iOnctura SA
Ionis Pharmaceuticals Inc
Isarna Therapeutics GmbH
Isterian Biotech Inc
Istesso Ltd
Iterion Therapeutics Inc
J2H Biotech
Jiangsu Hengrui Medicine Co Ltd
Joincare Pharmaceutical Group Industry Co Ltd
JW Pharmaceutical Corp
Kadmon Holdings Inc
KARE Biosciences Inc
Kinarus AG
Kintor Pharmaceutical Ltd
Kither Biotech Srl
Lamellar Biomedical Ltd
Lanier Biotherapeutics Inc
Lassen Therapeutics 1 Inc
LifeArc
Lignamed LLC
Liminal BioSciences Inc
Lispiro LLC
Lmito Therapeutics Co Ltd
Lotus Pharmaceutical Co Ltd
Mabwell Shanghai Bioscience Co Ltd
MannKind Corp
Max Biopharma Inc
Maxinovel Pharmaceuticals
MD Healthcare Inc
MDI Therapeutics Inc
Medical University of South Carolina
MediciNova Inc
Medispan
Melius Pharma AB
Metagone Biotech Inc
Metera Pharmaceuticals Inc
MetiMedi Pharmaceuticals Co Ltd
Mission Therapeutics Ltd
MitoImmune Therapeutics Inc
Molecure SA
MorphImmune
MyMD Pharmaceuticals Inc
Nankai University
National Institutes of Pharmaceutical R&D Co Ltd
National Jewish Health
National Taiwan University
NB Health Laboratory Co Ltd
New Amsterdam Sciences Inc
Nexel Co Ltd
Nextgen Bioscience
Nogra Pharma Ltd
Novartis AG
Novo Nordisk AS
NovoMedix LLC
Nuformix Plc
Oasis Pharmaceuticals LLC
Ocean Biomedical Inc.
Oleolive LLC
OliX Pharmaceuticals Inc
Omega Therapeutics Inc
Oncobix Co Ltd
Onegene Biotechnology Inc
Opsidio LLC
OptiKira LLC
OROX BioSciences Inc
Overseas Pharmaceuticals Ltd
Oxcia AB
Palo BioFarma SL
Panorama Research Institute
Pfizer Inc
Pharmaxis Ltd
Pieris Pharmaceuticals Inc
Pliant Therapeutics Inc
Prasan Pharmaceutical Consultants LLC
PRISM Pharma Co.
Ltd.
Pulmatrix Inc
Pulmongene Ltd
PulmoSIM Therapeutics
PureIMS BV
Puretech Health Plc
RDS2 Solutions Inc
Redx Pharma Plc
Regenasome Pty Ltd
Rejuvenation Technologies Inc
Remedy Cell Ltd
Reviva Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Ribomic Inc
Rohto Pharmaceutical Co Ltd
RS BioTherapeutics Inc
Rubedo Life Sciences Inc
Saje Pharma LLC
Saniona AB
Sanofi
Segue Therapeutics LLC
Senisca Ltd
Senolytic Therapeutics Inc
Shanghai Ark Biopharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Laifu Medical Technology Co Ltd
Shanghai Life Science & Technology
Shanghai Pharmaceuticals Holding Co Ltd
Shenzhen Tuwei Anchuang Technology Development Co Ltd
Shijiazhuang Sagacity New Drug Development Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Yiasuo Pharmaceutical Technology Co Ltd
SignalRx Pharmaceuticals Inc
Sino Biopharmaceutical Ltd
Sinovant Sciences HK Ltd
siRNAgen Therapeutics Corp
Sirnaomics Ltd
SiVEC Biotechnologies LLC
SK Chemicals Co Ltd
Spark Biopharma Inc
SpliSense Ltd
Structure Therapeutics Inc
Surrozen Inc
Suzhou Regend Therapeutics Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
SynDevRx Inc
Taiwan Liposome Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
TargetSite Therapeutics
Telomere Therapeutics
Tetragenetics Inc
Thirona Bio Inc
Thyron Pharmaceuticals Inc
Topadur Pharma AG
Trevi Therapeutics Inc
Tvardi Therapeutics Inc
Twinpigbiolab Co Ltd
UBE Corp
United Therapeutics Corp
University Hospital Freiburg
University of Strathclyde
VCANBIO Cell and Gene Engineering Corp Ltd
Vectus Biosystems Ltd
Velvio GmbH
Verona Pharma Plc
Vicore Pharma AB
Viridian Therapeutics Inc
Virtici LLC
VYNE Therapeutics Inc
Xfibra Inc
Yale University
Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Interstitial Lung Fibrosis reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Interstitial Lung Fibrosis – Drugs In Development, 2024 in real time.

  • Access a live Interstitial Lung Fibrosis – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more